









Markets
/
Stocks
/
nasdaq-uncy
/

Unicycive Therapeutics Inc

UNCY



View Detailed Chart

6.180USD

+0.060+0.98%

Close 01/09, 16:00（ET）Quotes delayed by 15 min

128.86MMarket Cap

LossP/E TTM



Unicycive Therapeutics Inc

6.180

+0.060+0.98%

Overview Company Financials Analysis

Overview

Company

Financials

Analysis

Intraday

30m

Today

+0.98%

5 Days

+6.55%

1 Month

-5.21%

6 Months

+14.87%

Year to Date

+7.11%

1 Year

-17.04%

View Detailed Chart

TradingKey Stock Score of Unicycive Therapeutics Inc

Currency: USD Updated: 2026-01-09

Key Insights

Unicycive Therapeutics Inc's fundamentals are relatively very healthy, and its growth potential is significant.Its valuation is considered fairly valued, ranking 138 out of 396 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 46.50.In the medium term, the stock price is expected to trend up.Despite an average stock market performance over the past month, the company shows strong technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Unicycive Therapeutics Inc's Score

Industry at a Glance

Industry Ranking

138 / 396

Overall Ranking

263 / 4562

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Negative

Unicycive Therapeutics Inc Highlights

StrengthsRisks

Unicycive Therapeutics, Inc. is a biotechnology company developing treatments for kidney diseases. The Company's lead drug candidate, oxylanthanum carbonate (OLC), is an investigational phosphate binding agent being developed for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis. Its second asset, UNI-494, is a patent-protected new chemical entity in clinical development for the treatment of conditions related to acute kidney injury.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 0.00.

Undervalued

The company’s latest PE is -1.78, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 6.53M shares, decreasing 4.49% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 658.88K shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of -0.79.